MERTK and neoplasm: Preclinical studies reinforce the idea that Mer-blockade, either by targeting the kinase domain or by using mAbs, can improve outcomes, particularly when combined with other therapies like radiation or checkpoint blockade to shift the immunosuppressive TME into a more immunogenic state, thereby inducing the adaptive immune response for long lasting anti-tumor immunity.